Do directly acting antiviral agents for HCV increase the risk of hepatic decompensation and decline in renal function? Results from ERCHIVES-Reference-Cited by-同舟云学术

Do directly acting antiviral agents for HCV increase the risk of hepatic decompensation and decline in renal function? Results from ERCHIVES

Published:2016-11-04 Issue:1 Volume:45 Page:150-159
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Butt A. A.¹²³⁴,Ren Y.¹,Marks K.⁴,Shaikh O. S.¹⁵,Sherman K. E.⁶,

Affiliation:

1. VA Pittsburgh Healthcare System; Pittsburgh PA USA

2. Weill Cornell Medical College; Doha Qatar

3. Weill Cornell Medical College; New York NY USA

4. Hamad Healthcare Quality Institute; Hamad Medical Corporation; Doha Qatar

5. University of Pittsburgh School of Medicine; Pittsburgh PA USA

6. University of Cincinnati; Cincinnati OH USA

Funder

AbbVie

Gilead Sciences

Anadys

Genentech

Merck

Novartis

Vertex

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.13837/fullpdf

Reference31 articles.

1. FDA FDA approves Viekira Pak to treat hepatitis C http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427530.htm

2. FDA FDA Drug Safety Communication: FDA warns of serious liver injury risk with hepatitis C treatments Viekira Pak and Technivie http://www.fda.gov/Drugs/DrugSafety/ucm468634.htm

3. Hepatic decompensation likely attributable to simeprevir in patients with advanced cirrhosis;Stine;Dig Dis Sci,2015

4. Lactic acidosis in patients with hepatitis C virus cirrhosis and combined ribavirin/sofosbuvir treatment;Welker;J Hepatol,2016

5. Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use;Dyson;J Hepatol,2016

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation;Journal of Hepatology;2021-12

2. Effect of Sofosbuvir/Ledipasvir and Glecaprevir/Pibrentasvir on Serum Creatinine;Journal of Clinical and Experimental Hepatology;2021-08

3. HCV cirrhotic patients treated with direct‐acting antivirals: Detection of tubular dysfunction and resolution after viral clearance;Liver International;2020-12-29

4. Eradication of hepatitis C virus infection in kidney transplant recipients using direct‐acting antiviral therapy: Qatar experience;Immunity, Inflammation and Disease;2020-12-02

5. Precipitating factors causing hyperbilirubinemia during chronic hepatitis C treatment with paritaprevir/ritonavir/ombitasvir and dasabuvir;Journal of the Chinese Medical Association;2020-12